Tanespimycin
Information
- Drug Name
- Tanespimycin
- Description
- Entry(CIViC)
- 6
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| lung non-small cell carcinoma | ALK EML4-ALK T1151INST | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 22277784 | Detail |
| lung non-small cell carcinoma | ALK p.Gly1202Arg (p.G1202R) ALK p.Gly1202Arg (p.G1202R) | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 22277784 | Detail |
| cancer | PIK3CA MUTATION PIK3CA MUTATION | D |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 2 | 25855885 | Detail |
| head and neck cancer | PTEN MUTATION PTEN MUTATION | D |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 2 | 25855885 | Detail |
| head and neck cancer | PIK3CA MUTATION PIK3CA MUTATION | D |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 2 | 25855885 | Detail |
| melanoma |
NRAS p.Gly13Asp (p.G13D) ( ENST00000369535.5 ) NRAS p.Gly13Asp (p.G13D) ( ENST00000369535.5 ) |
C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 18375819 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Ba/F3 cells transduced with EML4-ALK 1151 insT wer... | ALK | ALK EML4-ALK T1151INST | Sensitivity | true | CIViC Evidence | detail |
| The G1202R ALK mutation was found in a crizotinib-... | ALK | ALK p.Gly1202Arg (p.G1202R) ALK p.Gly1202Arg (p.G1202R) | Sensitivity | true | CIViC Evidence | detail |
| Analysis of drug response data from the Sanger cen... | PIK3CA | PIK3CA MUTATION PIK3CA MUTATION | Sensitivity | false | CIViC Evidence | detail |
| Analysis of drug response data from the Sanger cen... | PTEN | PTEN MUTATION PTEN MUTATION | Sensitivity | false | CIViC Evidence | detail |
| 6 head and neck cancer cell lines were tested for ... | PIK3CA | PIK3CA MUTATION PIK3CA MUTATION | Sensitivity | false | CIViC Evidence | detail |
| Likely due to increased reliance of mutant NRAS on... | NRAS |
NRAS p.Gly13Asp (p.G13D) ( ENST00000369535.5 ) NRAS p.Gly13Asp (p.G13D) ( ENST00000369535.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00779428 | Completed | Phase 2 | Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin | July 2006 | July 2013 |
| NCT00004065 | Completed | Phase 1 | Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer | July 1999 | March 2005 |
| NCT00004075 | Completed | Phase 1 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery | August 1999 | January 2007 |
| NCT00004241 | Completed | Phase 1 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma | October 1999 | |
| NCT00121264 | Completed | Phase 1 | 17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors | March 2005 | July 2010 |
| NCT00132015 | Completed | Phase 2 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis | May 2006 | June 2008 |
| NCT00514371 | Completed | Phase 2/Phase 3 | A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma | August 2007 | February 2009 |
| NCT00546780 | Completed | Phase 3 | A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse | February 2008 | March 2010 |
| NCT00577889 | Completed | Phase 2 | Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer | March 2008 | May 2013 |
| NCT00773344 | Completed | Phase 1/Phase 2 | Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin | December 2005 | August 2009 |
| NCT00003969 | Completed | Phase 1 | Geldanamycin Analogue in Treating Patients With Advanced Cancer | August 1998 | January 2007 |
| NCT00047047 | Completed | Phase 1 | Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors | August 2002 | |
| NCT00058253 | Completed | Phase 1 | Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors | February 2003 | March 2010 |
| NCT00066326 | Completed | Phase 1 | Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia | June 2003 | September 2005 |
| NCT00079404 | Completed | Phase 1 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | March 2004 | |
| NCT00087217 | Completed | Phase 1 | 17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor | May 2004 | |
| NCT00093405 | Completed | Phase 2 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer | August 2004 | November 2005 |
| NCT00093496 | Completed | Phase 2 | Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer | October 2007 | March 2012 |
| NCT00093821 | Completed | Phase 1 | Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors | September 2004 | |
| NCT00098423 | Completed | Phase 1 | Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes | November 2004 | |
| NCT00100997 | Completed | Phase 1 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate | October 2004 | October 2006 |
| NCT00104897 | Completed | Phase 2 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma | March 2005 | November 2010 |
| NCT00117988 | Completed | Phase 2 | 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma | February 2005 | April 2010 |
| NCT00118092 | Completed | Phase 2 | 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy | January 2005 | February 2008 |
| NCT00118248 | Completed | Phase 2 | Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer | December 2004 | April 2012 |
| NCT00119236 | Completed | Phase 1 | 17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors | May 2005 | |
| NCT00019708 | Terminated | Phase 1 | Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | June 1999 | |
| NCT00103272 | Terminated | Phase 1 | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer | April 2005 | |
| NCT00098488 | Terminated | Phase 1 | 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia | April 2005 | |
| NCT00354185 | Terminated | Phase 1 | PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma | May 2006 | |
| NCT00096005 | Terminated | Phase 1 | Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | November 2004 | |
| NCT00096109 | Terminated | Phase 2 | Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer | September 2005 | May 2012 |
| NCT00087386 | Terminated | Phase 2 | Tanespimycin in Treating Patients With Stage III-IV Melanoma | June 2004 |